Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study
Early local therapy, especially those performed after effective systemic therapy and targeting all tumor lesions, may prolong patient's survival in PD-1/PD-L1 inhibitor-treated oligometastatic NSCLC.
Authors
- Jianjiao Ni (ORCID: https://orcid.org/0000-0003-3113-2586)
- Silai Yu
- Aihua Lan (ORCID: https://orcid.org/0000-0002-8838-7582)
- Jie Hu (ORCID: https://orcid.org/0000-0002-6956-4651)
- Xiao Chu (ORCID: https://orcid.org/0000-0002-1630-0388)
- Jie Gao (ORCID: https://orcid.org/0000-0003-1327-7853)
- Xi Yang (ORCID: https://orcid.org/0000-0002-9843-3925)
- Yue Zhou (ORCID: https://orcid.org/0000-0003-4012-4270)
- Yechun Pang
- Hongru Chen
- Qian Chu (ORCID: https://orcid.org/0000-0001-8192-7630)
- Zhengfei Zhu
- Li Chu
Institutions
- Shanghai Medical College of Fudan University (CN)
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanghai Clinical Research Center (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1007/s00262-025-04016-0
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09